From Plasmids to Cell-free DNA for Advanced Gene Therapies

In gene therapy manufacturing, viral vectors have long been the primary method for gene modification. However, recent innovations, combined with the evolving demands of the genetic medicines market, are driving a shift toward non-viral technologies. To address this need, the research team at Touchlight, leaders in the industrialisation of cell-free DNA and its application in genetic medicines, initiated development of a novel platform named Megabulb DNA (mbDNA).

In this executive summary, you’ll learn:

• Why mbDNA is redefining precision gene editing
• How mbDNA dramatically improves cell viability and edited cell yields
• How mbDNA delivers proven performance in real-world applications with ElevateBio